[An update on the susceptibility of Stenotrophomonas maltophilia].
Sevillano
D
D
Departamento de Microbiología I, Facultad de Medicina, Universidad Complutense de Madrid, Spain.
Valdezate
S
S
Gómez-Lus
M L
ML
D000900:Anti-Bacterial Agents / Q000145:classification / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000235:genetics / Q000502:physiology; D015373:Bacterial Typing Techniques; D001692:Biological Transport; D002352:Carrier Proteins / Q000235:genetics / Q000502:physiology; D002463:Cell Membrane Permeability; D015897:Comorbidity; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D003550:Cystic Fibrosis / Q000150:complications / Q000453:epidemiology; D004250:DNA Topoisomerases, Type II / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics / Q000502:physiology; D018432:Drug Resistance, Multiple / Q000235:genetics / Q000502:physiology; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005500:Follow-Up Studies; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D020128:Inhibitory Concentration 50; D008826:Microbial Sensitivity Tests / Q000379:methods; D015995:Prevalence; D015203:Reproducibility of Results; D020615:Stenotrophomonas maltophilia / Q000145:classification / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D001618:beta-Lactamases / Q000235:genetics / Q000502:physiology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002352:Carrier Proteins; D001618:beta-Lactamases; D004250:DNA Topoisomerases, Type II